COMP <GO>
WST vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
West Pharmaceutical Services Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: WST 5
— ABBV 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $416.67 (+3.23%) • MKT CAP: $29.32B
roic
17.90%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WST VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | WST | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.90% | 70.20% | -34.30 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 17.90% | 29.00% | -11.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 34.7x | 33.3x | +1.40 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 1.60% | 3.47% | -1.87 | ABBV | /fcf-yield <GO> |
| Operating Margin | 19.00% | 24.60% | -5.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 16.10% | 6.90% | +9.20 | WST | /net-margins <GO> |
| Revenue Growth (YoY) | 6.30% | 8.60% | -2.30 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.21% | 2.27% | -2.06 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 19.06 | 5.33 | +13.73 | WST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | WST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 77.0 | 65.1 | +11.90 | WST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 55.2x | 113.1x | -57.90 | WST | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.32B | $513.86B | -$484.54B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | WST REV | ABBV REV | WST GROSS % | ABBV GROSS % | WST FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.07B | $61.16B | 35.9% | 70.2% | $468.9M | $17.82B |
| FY 2024 | $2.89B | $56.33B | 34.5% | 70.0% | $276.4M | $17.83B |
| FY 2023 | $2.95B | $54.32B | — | — | $643.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WST // BETA 1.08
ABBV // BETA 1.15